Lupus & antiphospholipid syndrome
Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: A retrospective single-center analysis in Japan
Main finding · APO incidenceResult — go to the resultAdjusted odds ratio 1 95% CI 0.23–4.39Authors' conclusion
Tacrolimus did not significantly affect pregnancy outcomes, blood pressure, or glucose levels.
Study context
- Population
- Pregnancies complicated by Systemic Lupus Erythematosus (SLE), St Luke's International Hospital, Tokyo, April 2003 to August 2021
- Participants
- 48 participants60 pregnancies
- Exposure
- Tacrolimus vs no tacrolimus during SLE pregnancies
- Tacrolimusn = 20
- Outcome
- Overall adverse pregnancy outcomes (APOs): fetal death after 10 gestational weeks, preterm delivery, delivery due to hypertensive disorders of pregnancy, preeclampsia or placental insufficiency, or small for gestational age infants
Methodological detailssingle-centre, observational
- Single-centre
- Observational
Main finding
APO incidence
Adjusted odds ratio
1
95% CI 0.23–4.39
P = 1.00
Tacrolimusvs Non-tacrolimus
aOR 1 (95% CI 0.23–4.39); P = 1.00
As reported in the abstract
- Adverse pregnancy outcomes (APOs) in all pregnancies
- 28 (46.7%)
Observational data: associations, not effects.
Further findings
| Outcome | B | P value |
|---|---|---|
| Systolic blood pressure, third trimester (multiple regression) | −2.23 | P = 0.74 |
| Blood glucose, first trimester (multiple regression) | 10.2 | P = 0.056 |
Safety
Incidence of infections · univariate analysis
P = 0.42
Original publication
Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: A retrospective single-center analysis in Japan. Lupus. Published 12 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →